From the makers of
Track & Manage All Of Your Investments
Try It Now!
New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
NeurogesX (NGSX)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for NeurogesX
Acetaminophen Prodrug Candidates-preclinical Program
Acquisition Bonus Plan
Acquisition Bonus Plan Amended 2008
Additional Studies Phn
Adopted 2008
Adopted 2009
Adoption New Accounting Standard
Adoption Sfas 123r
Alterations Additions
Amendment Lease
Anthony Ditonno
Anthony Ditonno Continuing Remarks
Anthony Ditonno Remarks
Anthony Ditonno Wrap-up Statement
Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition
Approvals Outside United States European Union
Approved Peripheral Neuropathic Pain Non-diabetic Adults
Astellas Pharma Europe Ltd
Available Information
Background
Base Compensation
Basis Presentation
Batch Accompanying Documentation
Batch Prices
Benchmarking Elements Compensation
Beneficial Ownership Reporting Compliance
Board Meetings Committees
Bonus Compensation
Bridgepointe Parkway Suite 200
Building 2215 Bridgepointe Parkway San Mateo
Call Scheduled 2009 9am
Cannot Predict Whether Regulatory Agencies Determine Data Clinical
Cannot Predict Whether Regulatory Agencies Determine Data Ngx-4010
Capsaicin Dermal Patch Since 2009
Capsaicin-induced Effects Peripheral Neuropathic Pain
Carol Ruth Safe Harbor
Cash Equivalents Short Term Investments
Changes Financial Condition
Chmp Commitment
Clinical Development Update
Clinical Trial Phases
Clinical Trial Results
Clinical Trials
Clinical Trials Fail Demonstrate Adequately Safety Efficacy Product
Code Ethics
Collaboration Agreement Astellas
Collaboration Arrangements
Commencement Agreement
Commercial Success Ngx-4010 Depends Part Rights Certain Patents
Commercial Success Qutenza Depends Part Rights Certain Patents
Commercial Supply License Agreement
Commercialization
Commitments Contingencies
Common Stock
Comparison 2006 2005
Comparison 2007 2006
Comparison 2008 2007
Comparison 2009 2008
Comparison Historical Cumulative Total Return Among Neurogesx Inc
Compensation Committee Interlocks Insider Participation
Compensation Philosophy Objectives
Competition
Comprehensive Loss
Concentrations Credit Risk Financial Instruments
Conference Call Details
Conference Call Scheduled Friday 9am
Conference Call Webcast Information
Confidentiality
Consent Independent Registered Public Accounting Firm
Continue Incur Increased Costs Demands Management Result Complying
Contractual Obligations
Cooperation Terms
Coordination
Corporate Highlights
Critical Accounting Policies Significant Judgments Estimates
Cubes-standard Kimball Cetra Footprint Furniture Contain
Data Exclusivity
Deadline Receipt Stockholder Proposals
Deferred Offering Costs
Deferred Stock Based Compensation
Deferred Stock-based Compensation
Definitions
Delays Commencement Completion Clinical Testing Result Increased Costs
Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Depend Key Personnel Not Able Retain Them Business
Development
Development Plan
Development Stage
Development Update
Director Compensation
Directors Executive Officers
Discussion Analysis Read Conjunction Financial Statements Accompanying Notes
Dispute Resolution
Distribution Marketing License Agreement
Documentation Provided Ngx
Documents Incorporated Reference
Effects Termination
Elizabeth Scott Safe Harbor
Employees
Employment Agreements
End 2007 Financial Results
Enter Agreement Depend Partners Assist Commercializing Lead Product
Entry Material Definitive Agreement
Equity Awards
Estimates
Estimation Fair Value Warrants Purchase Redeemable Convertible Preferred
European Union
Europeregistrycom
Even Clinical Trials Ngx-4010 Treatment Phn Hiv-dsp Successful
Even Product Candidates Receive Regulatory Approval They Subject
Events Credit Markets Continue Impact Investment Returns
Exact Name Registrant Specified Charter
Except Share Per Data
Exchange Act 1934 Amendment
Executive Compensation
Executive Employment Agreement
Exhibits
Existing Treatments Limitations
Expect Stock Price Fluctuate Significantly Not Able Resell
Explanatory
Face Potential Product Liability Exposure Successful Claims Brought
Face Substantial Competition Result Others Discovering Developing Commercializing
Facilities
Fail Comply Obligations Agreements License Development Commercialization Rights
Fair Value Measurements
Fair Value Warrants Issued
Fast Track Designation Development Ngx-4010 Treatment Painful Hiv-associated
Fast Track Designation Development Qutenza Treatment Painful Hiv-associated
Fast Track Designation Priority Review
Financial Results
Financial Statements Exhibits
Follow-up Measures
Foreign Currency Exchange Rate Risk
Form 10-k
Form 10-q
Form Letter Credit
Form Organization
Former Address
Former Name Address Changed Since Last Report
Formosa Laboratories Inc
Future Sales Shares Existing Stockholders Cause Stock Price
General
Grant Exercise Option Landlord Grants Tenant Lease Building
Grants Plan-based Awards
Guarantees Indemnifications
Hatch-waxman Act
Highlights
Immediate Release
Includes Licensing Option Development Funding Ngx-1998
Income Taxes
Incur Increased Costs Demands Management Result Complying Laws
Incur Substantial Costs Result Litigation Other Proceedings Relating
Incurred Operating Losses Each Since Inception Expect Continue
Indebtedness Management
Indemnification
Indemnification Directors Officers
Independence Directors
Independent Registered Public Accounting Firm Ending 2008
Independent Registered Public Accounting Firm Ending 2009
Index
Index Consolidated Financial Statements
Initial Payments Milestones
Initial Public Offering
Initial Public Offering Proceeds
Initial Subtenant Alterations
Instrument Adherence
Intellectual Property
Interest Expense
Interest Rate Market Risk
Internet Availability Proxy Materials
Inventory
Investor Name Address
Jeffrey Tobias
Jeffrey Tobias Remarks
Jsc Commercialization Plan Existing Product
Keith Bley Phd
Key Metrics
Landlords Liability
Lead Product Candidate Ngx-4010
Legal Opinion
Liability
License Agreement
Licenses
Limited Experience Regulatory Affairs
Liquid Formulation Ngx-1998
Liquidity Capital Resources
Lts Agreement
Lts Lohman Therapie-systeme
Lts Lohmann Therapie-systeme
Management Auditors Identified Material Weaknesses Internal Controls Part
Manufacturing
Manufacturing Capabilities Depend Other Parties Operations Manufacturers Fail
Manufacturing Process Development
Manufacturing Supply Agreement
Marketing Application Submitted Schedule
Marketing Approval Including Packaging Information Specifications Also Include
Marketing Authorization
Marketing Authorizations Regulatory
Material Weaknesses Identified Prior
Maximum Capacity
Maximum Order Quantity
Michael Markels
Miscellaneous
Name Person Filing Proxy Statement Other Registrant
Nature Operation Basis Preparation
Nature Operations
Net Loss Per Share
Networksolutionscom
Neurogesx Appoints New Director Board
Neurogesx Inc
Neurogesx Ngx-4010 Maa Filed Accepted Review Emea Treatment
Neurogesx Receives Fda Approval Qutenza Capsaicin Patch Treatment
Neuropathic Pain
Neuropathic Pain Conditions
Never Paid Dividends Capital Stock Not Anticipate Paying
New Drug Application
Ngx-1998-liquid High Concentration Topical Capsaicin
Ngx-4010
Ngx-4010-initial Target Indications
Ngx-6052 Opioid Analgesic Prodrug Preclinical Program
Nominees
Not Able Maintain Orphan Drug Exclusivity Qutenza Phn
Not Able Obtain Hatch-waxman Act Data Exclusivity Equivalent
Not Able Obtain Hatch-waxman Act Marketing Exclusivity Equivalent
Not Able Obtain Maintain Orphan Drug Exclusivity Ngx-4010
Not Able Obtain Maintain Orphan Drug Exclusivity Qutenza
Not Raise Additional Capital Forced Delay Reduce Eliminate
Not Raise Additional Capital Forced Further Delay Reduce
Not Successful Obtaining European Regulatory Approval Ngx-4010
Not Successful Obtaining European Regulatory Approval Qutenza
Not Yet Adopted
Notes Receivable Stockholders
Off-balance Sheet Arrangements
Only Prescription Strength Capsaicin Product Provide Reduced Pain
Operating Leases
Operator
Opioid Analgesic Prodrugs-preclinical Program
Options Exercised Stock Vested
Orphan Drug Designation
Other Benefits
Other Events
Other Matters
Other Regulatory Requirements
Overview
Overview Compensation Program
Ownership Common Stock Continues Highly Concentrated Prevent Other
Ownership Licenses
Painful Diabetic Neuropathy
Painful Hiv-distal Sensory Polyneuropathy
Part
Part Other Information
Patents Proprietary Rights
Patient Study Evaluate Fda-approved Topical Anesthetic Pretreatment
Payment
Payments
Payments Books Records
Persons Contact
Phn Hiv-dsp
Physicians Not Adequately Reimbursed Time Services Administering Ngx-4010
Physicians Not Adequately Reimbursed Time Services Administering Qutenza
Policies Procedures Related Party Transactions
Postherpetic Neuralgia
Postherpetic Neuralgia Phn
Potential Market Exclusivity Phn Pending Product Approval
Potential Payments Termination Change Control
Power Attorney
Preclinical Studies
Preferred Stock Warrant Liability
Preferred Stock Warrant Liability Redeemable Convertible
Preferred Stock Warrants
Premises
Prepaid Collaboration Supplies
Present
Press Release
Principal Accountant Fees Services
Principles Consolidation
Private Placement
Pro Forma Information
Product Candidates Never Achieve Market Acceptance Even Obtain
Product Candidates Never Achieve Market Acceptance Even They
Product Description
Product Development Programs
Product Trademark Alternative
Product Warranties
Products Expected Face Substantial Competition Result Others Discovering
Property Equipment
Purchase Order
Purchase Order Form
Purchase Order Number Appear Invoices Correspondence
Purchasers Certificate Subsequent Sale
Pursuant 302 Sarbanes-oxley Act 2002
Q09 Corporate Highlights
Quality
Quality Agreement
Quality Regulatory Issues
Quorum Abstentions Broker Non-votes
Qutenza
Qutenza Since 2009
Raising Additional Funds Issuing Securities Through Licensing Arrangements
Receives Nasdaq Notice Regarding Audit Committee Compliance
Recent Developments
Recent Events Credit Markets Continue Impact Investment Returns
Recent Events Credit Markets Increased Risk Cash Equivalents
Recently Issued Accounting Standards
Recitals
Record Date Share Ownership
Regains Nasdaq Compliance
Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 650 358-3300
Registrants Telephone Number Including Area Code 650 508-2116
Regulation Disclosure
Regulatory Commercialization Plans Ngx-4010
Regulatory Matters
Regulatory Reviews Now Underway Europe
Rely Parties Conduct Clinical Trials Not Perform Contractually
Rely Parties Conduct Non-clinical Clinical Trials Not Perform
Rely Parties Conduct Non-clinical Studies Clinical Trials Not
Remainder Page Intentionally Left Blank
Remediation Prior Material Weaknesses
Rental Adjustment
Report Audit Committee Board Directors
Report Compensation Committee Board Directors
Report Independent Registered Public Accounting Firm
Representations Warranties
Representations Warranties Disclaimer Limitation Liability
Require Substantial Additional Funding Unable Raise Capital Needed
Research Development
Restated Executive Employment Agreement
Restricted Stock Purchases
Results Fda-requested Qutenza Study
Results Operations
Results Operations Financial Condition
Revenue Recognition
Reverse Stock Split
Revocability Proxies
Risk Factors
Risks Related Business
Risks Related Finances Capital Requirements
Role Executive Officers Compensation Decisions
Rules Regulations
Safe Harbor Statement
Sales Marketing Distribution
Sarbanes-oxley Act 2002
Schedule Purchasers
Schedules Investor Conference Call 500 Est
Securities Exchange
Securities Exchange Act 1934
Securities Registered Pursuant Act
Security Deposit
Services
Severance Change Control Payments
Shares Reserved Future Issuances
Shares Warrants Issued Insiders
Signatures
Signatures Next Page
Solicitation Proxies
Solution
Stability Testing Program
Standard Private Offices Kimball Cetra Footprint Furniture Contain
Stephen
Stephen Ghiglieri
Stock Incentive Plan
Stock Incentive Plan 2007
Stock Options Granted Nonemployees
Stock Plan
Stock-based Compensation
Stockholders Equity
Strategy
Subject Damages Resulting Claims Employees Wrongfully Used Disclosed
Success Depend Part Successful Efforts Collaboration Partner European
Success Depends Ability Obtain Regulatory Approval Lead Product
Success Depends Substantially Ability Obtain Regulatory Approval Lead
Sued Infringing Intellectual Property Rights Other Parties Such
Supply
Supply Agreement
Supply Existing Product
Susan Rinne
Term Termination
Territory
Text Initial Patch Backing
Third-party Reimbursement Pricing Controls
Tony Ditonno
Trademarks
Transfer Marketing Authorisation
Transfer Price
Trg
Trial Meets Primary Secondary Endpoints
Unable Establish Sales Marketing Distribution Infrastructure Enter Collaborations
Unable Maintain Enforce Proprietary Rights Not Able Compete
United States
University California
Upcoming 2009 Milestones
Vote Required
Voting
Vr1-ligands
Warrant Exercises
Warrants Purchase Common Stock
Witnesseth
Wttnesseth
Year-end 2008 Financial Results
Skip the spreadsheet. Track your investments automatically.
Start now